Oxycodone

Introduction Overview

Generic Name

Oxycodone

Brand Name

OxyCONTIN, Roxicodone, RoxyBond, Xtampza ER, Oxaydo

Dosage Form

capsule, extended-release capsule, oral solution, tablet, extended-release tablet, abuse-deterrent tablet

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Absorption:
Oxycodone is well absorbed orally with an onset of analgesic effect typically within 10 to 30 minutes for immediate-release preparations. Peak plasma concentrations generally occur between 1 to 1.5 hours post-dose for immediate-release forms, and sustained release formulations exhibit extended absorption profiles allowing therapeutic plasma levels to be maintained for up to 12 hours. Food intake can delay the time to peak concentration but does not significantly affect the extent of absorption. The oral bioavailability is approximately 60-87%, influenced by first-pass hepatic metabolism. Clinical studies indicate that both immediate- and extended-release formulations provide effective analgesia, with extended-release forms optimizing steady-state plasma concentrations to manage chronic pain.

Distribution:
After systemic absorption, oxycodone exhibits a volume of distribution of approximately 2.6 to 4.8 L/kg, reflecting wide tissue distribution including crossing the blood-brain barrier to act on central nervous system opioid receptors. Plasma protein binding is moderate at around 45%. The drug permeates the central nervous system efficiently due to its lipophilic nature, targeting μ-opioid receptors for analgesic effects. Distribution characteristics support both rapid onset of action with immediate-release formulations, and sustained CNS exposure with extended-release forms to provide continual pain control.

Metabolism:
Oxycodone undergoes extensive hepatic metabolism predominantly via cytochrome P450 enzymes CYP3A4 and CYP2D6. The primary metabolic pathways include N-demethylation by CYP3A4 to noroxycodone (inactive) and O-demethylation by CYP2D6 to oxymorphone (active metabolite with greater opioid potency). Genetic polymorphisms affecting CYP2D6 activity can influence oxycodone metabolism and clinical response. Additionally, interactions with CYP3A4 inhibitors or inducers may alter plasma concentrations, necessitating dose adjustments. Phase II conjugation reactions also occur, forming glucuronide conjugates excreted renally.

Elimination:
Elimination of oxycodone and its metabolites is primarily via renal excretion, with approximately 10-20% of unchanged drug recovered in urine, and the remainder as metabolites. The elimination half-life ranges from 3 to 4.5 hours for immediate-release formulations, while extended-release products maintain therapeutic levels over 8 to 12 hours. Renal impairment can affect clearance leading to drug accumulation, requiring cautious dosing in affected patients. Hepatic dysfunction similarly impacts metabolism and elimination, increasing the risk for toxicity. The drug is also detectable in saliva, urine, and hair for extended periods, relevant for clinical monitoring and abuse detection.

Dosage Forms

Available Dosage Forms:
- Immediate-release tablets: 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg
- Immediate-release, abuse-deterrent tablets: 10 mg
- Immediate-release capsules: 5 mg
- Immediate-release oral solution: 5 mg per 5 mL (1 mg/mL) and 100 mg per 5 mL (20 mg/mL)
- Extended-release tablets: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg

Dosages for Adults and Adolescents:
- Immediate-release formulations are typically dosed every 4 to 6 hours as needed for acute pain management, with initial doses ranging from 5 mg to 15 mg depending on clinical context and patient opioid tolerance.
- Extended-release formulations are intended for around-the-clock management of chronic moderate to severe pain and are usually given twice daily. Initial doses should be conservative in opioid-naïve patients to avoid respiratory depression.
- Dose titration is individualized based on analgesic response and tolerability. Conversion from other opioids or between oxycodone formulations requires clinical judgment due to differing pharmacokinetic profiles.

Specific Patient Populations:
- In elderly patients, initiation at the lowest possible dose is recommended due to increased sensitivity and risk for respiratory depression and sedation.
- Patients with hepatic or renal impairment require dose adjustments due to altered metabolism and elimination.
- Immediate-release products are preferred for short-term use; extended-release formulations are reserved for patients requiring continuous opioid therapy.
- Use during pregnancy and breastfeeding is cautioned against given risks of neonatal opioid withdrawal syndrome and infant respiratory depression; benefits must be carefully weighed.

Clinical Guidelines:
- Extended-release oxycodone is contraindicated for as-needed pain relief or in opioid-naïve patients without careful titration.
- Abuse-deterrent formulations are designed to reduce misuse but do not eliminate risk.
- Liquid formulations provide dose flexibility for patients unable to swallow tablets or requiring precise dosing adjustments.

Mechanism Of Action

Oxycodone exerts its pharmacological effects primarily through agonism at the μ-opioid receptors located in the central nervous system and peripheral tissues. Binding to these G-protein coupled receptors induces conformational changes that inhibit adenylate cyclase activity, leading to decreased cAMP production and subsequent modulation of ion channel activity. This cascade results in hyperpolarization of neurons, decreasing excitability and neurotransmitter release, thereby diminishing the transmission of nociceptive signals.

At the cellular level, oxycodone reduces neuronal excitability by enhancing potassium efflux and reducing calcium influx in presynaptic terminals. This action suppresses neurotransmission in pain pathways, particularly within the dorsal horn of the spinal cord and supraspinal structures such as the thalamus and limbic system, which are involved in pain perception and emotional response to pain.

Biochemically, oxycodone and its active metabolite oxymorphone share affinity for μ-opioid receptors with high selectivity, which accounts for their potent analgesic properties. Unlike some opioids, oxycodone exhibits minimal affinity for kappa and delta opioid receptors, contributing to its characteristic analgesic profile and reduced dysphoric side effects common to kappa agonism.

Clinically, this mechanism translates into effective management of moderate to severe pain through both immediate and sustained receptor activation, depending on the formulation. Research has demonstrated that oxycodone’s analgesic potency is comparable to morphine but with a slightly different side effect profile. Furthermore, oxycodone’s abuse potential mandates careful patient selection and monitoring. Comparative studies also show that extended-release formulations provide consistent plasma levels, improving pain control while minimizing peaks and troughs that can lead to side effects or breakthrough pain.

Pharmacological Actions

Potent agonist of μ-opioid receptors providing analgesic effects
Modulation of central nervous system pain pathways to reduce nociceptive transmission
Induction of neuronal membrane hyperpolarization leading to decreased neurotransmitter release
Reduction of perception of pain and emotional response to pain stimuli
Exhibits sedative and euphoric properties contributing to analgesia
Causes respiratory depression by acting on brainstem respiratory centers
Suppresses cough reflex through medullary cough center depression
Can induce miosis (pinpoint pupils) through parasympathetic stimulation
Decreases gastrointestinal motility resulting in constipation
Has potential for physical dependence and tolerance with prolonged use
Exerts immunomodulatory effects, potentially suppressing immune system function
Influences hormone release via hypothalamic-pituitary axis modification
Produces CNS depression leading to drowsiness and sedation
May cause nausea and vomiting through stimulation of chemoreceptor trigger zone
Active metabolite oxymorphone contributes to overall analgesic efficacy

Therapeutic Or Clinical Uses

Management of moderate to severe acute pain when alternative treatments are inadequate
Chronic pain management requiring continuous opioid analgesia, such as cancer-related pain
Postoperative pain control in both inpatient and outpatient settings
Treatment of pain associated with trauma or injury
Adjunctive therapy for pain unresponsive to non-opioid analgesics
Use in patients with intolerance or contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs)
Management of severe pain in palliative and end-of-life care
Pain relief in patients with chronic non-malignant conditions after rigorous assessment
Specific use of extended-release formulations for around-the-clock pain control
Immediate-release tablets and solutions for breakthrough pain episodes
Use in opioid rotation or switching protocols to optimize pain control and minimize side effects
Consideration in combination with non-opioid analgesics for multimodal pain management
Use limited by potential for abuse and dependence, hence reserved for carefully selected patients
Short-term use for acute pain following surgical interventions
Inclusion in opioid analgesic REMS program to limit misuse and overdose

Side Or Adverse Effects

Common adverse effects include headache, nausea, and vomiting
Constipation is a frequent and persistent side effect due to decreased gastrointestinal motility
Drowsiness and sedation leading to impaired cognitive and motor function
Dizziness and lightheadedness increasing fall risk, especially in elderly patients
Pruritus, flushing, and redness of eyes due to histamine release
Respiratory depression possibly resulting in life-threatening hypoventilation
Potential for opioid-induced hyperalgesia with long-term use
Risk of tolerance, dependence, and opioid use disorder with chronic administration
Withdrawal symptoms including agitation, diarrhea, and muscle pain upon abrupt cessation
Urinary retention especially in patients with underlying urinary tract obstruction
Hypotension or syncope secondary to peripheral vasodilation
Confusion, hallucinations, or other neuropsychiatric symptoms in sensitive populations
Seizures have been reported rarely, particularly in overdose or predisposed individuals
Elevated serotonin syndrome risk when combined with serotonergic drugs
Allergic reactions ranging from mild rash to severe anaphylaxis

Precautions

Use with caution in patients with respiratory disorders including asthma and chronic obstructive pulmonary disease
Dose adjustments necessary in hepatic and renal impairment due to altered metabolism and clearance
Gradual tapering recommended to avoid withdrawal symptoms when discontinuing therapy
Risk of sedation and impaired mental alertness warrants avoidance of hazardous activities
Avoid use in patients with a history of drug or alcohol abuse to mitigate addiction potential
Careful monitoring for signs of misuse, abuse, or diversion is essential
Use extreme caution in elderly or debilitated patients due to increased susceptibility to respiratory depression
Pregnancy risk includes neonatal opioid withdrawal syndrome; use only if benefits justify risks
Breastfeeding mothers should avoid oxycodone or monitor infants closely for sedation and respiratory issues
Avoid concomitant use with other CNS depressants unless under strict medical supervision
Monitor for serotonin syndrome when administered with serotonergic agents
Opioid-induced adrenal insufficiency is a potential but rare occurrence requiring vigilance
Consider genetic polymorphisms of CYP2D6 that may affect drug metabolism and response
Educate patients on safe storage and disposal of medication to prevent accidental ingestion
Avoid abrupt discontinuation to minimize withdrawal symptoms and rebound pain

Warnings

Boxed warnings include risks of addiction, abuse, and misuse leading to overdose and death
Serious or fatal respiratory depression can occur, especially in opioid-naïve patients
Fatal respiratory depression risk increases with concomitant use of benzodiazepines or other CNS depressants
Accidental ingestion by children can result in fatal overdose
Use during pregnancy may cause neonatal opioid withdrawal syndrome with life-threatening consequences
Patients should be monitored regularly under the Opioid Analgesic REMS program to ensure safe use
Do not use extended-release oxycodone for as-needed pain relief due to overdose risk
Avoid concomitant use with CYP3A4 inhibitors as plasma concentrations may increase, enhancing toxicity
Risk of fatal overdose increases with consumption of alcohol or illicit drugs alongside oxycodone
Prescribers should assess risk versus benefit carefully before initiating therapy
Misuse can lead to addiction even at prescribed doses due to euphoric effects
Overdose treatment requires immediate administration of opioid antagonists such as naloxone
Patients with a history of substance abuse require specialized monitoring and treatment plans
Driving or operating machinery is contraindicated until drug effects are known
Abrupt cessation in dependent patients can precipitate withdrawal and adverse clinical outcomes

Contraindication

Known hypersensitivity or allergy to oxycodone or any component of the formulation
Severe respiratory depression or compromised respiratory function such as severe asthma
Paralytic ileus or significant gastrointestinal obstruction
Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
Patients with acute or severe bronchial asthma
Known or suspected cases of gastrointestinal obstruction due to risk of worsening condition
Use in patients with respiratory conditions involving hypoxia or hypercapnia
Do not use in opioid-naïve patients for extended-release formulations intended for chronic pain
Avoid use in those with significant CNS depression due to risk of additive effects
Patients undergoing bariatric surgery due to altered absorption and increased overdose risk
Contraindicated in patients with paralytic ileus or symptoms suggestive of gastrointestinal blockage
Patients with severe hepatic impairment without dose modification and careful monitoring
Use in combination with other potent CYP3A4 inhibitors is contraindicated unless benefits outweigh risks
Concomitant use with benzodiazepines or other CNS depressants contraindicated except under close supervision
Known or suspected opioid hypersensitivity including anaphylaxis history

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase oxycodone plasma levels, enhancing toxicity risk
CYP3A4 inducers (e.g., rifampin, carbamazepine) decrease oxycodone effectiveness by reducing plasma concentrations
Concomitant use with other opioids increases risk of respiratory depression and sedation
Benzodiazepines and other CNS depressants potentiate sedative and respiratory depressant effects
Monoamine oxidase inhibitors (MAOIs) may cause severe interactions including serotonin syndrome
Serotonergic drugs (e.g., SSRIs, SNRIs) can precipitate serotonin syndrome
Alcohol consumption can exacerbate CNS depression and respiratory failure
Muscle relaxants enhance CNS depressant effects leading to profound sedation
Antiretroviral medications (e.g., ritonavir) interacting via CYP3A4 modulation alter oxycodone levels
Antifungal agents such as itraconazole can raise oxycodone blood levels causing toxicity
Use with sedative hypnotics or tranquilizers increases risk of hypotension and respiratory depression
Certain antiemetics and migraine medications may interact and increase side effect risk
Diuretics and antihypertensives may have altered efficacy secondary to oxycodone-induced vasodilation or fluid retention
Drugs for irritable bowel syndrome or overactive bladder may interact altering gastrointestinal motility
Herbal supplements like St. John's Wort can induce CYP3A4, reducing oxycodone efficacy

Preparations Of The Drug

Immediate-release tablets available in 5 mg, 10 mg, 15 mg, 20 mg, 30 mg strengths for acute pain management
Abuse-deterrent immediate-release tablets formulated at 10 mg to reduce potential misuse
Immediate-release capsules commonly available as 5 mg capsules for titration flexibility
Oral solutions formulated as 1 mg/mL and 20 mg/mL for patients requiring liquid dosage forms
Extended-release tablets ranging from 10 mg to 80 mg providing sustained analgesic effect over 12 hours
Extended-release capsules (e.g., Xtampza ER) with abuse-deterrent properties to minimize abuse potential
Brand names including OxyCONTIN for sustained-release tablets, Roxicodone for immediate-release tablets
RoxyBond and Oxaydo formulations designed with proprietary abuse-deterrent technologies
Packaging designed to ensure stability at room temperature away from moisture and heat
Dosing syringes or calibrated measuring devices provided with oral solutions for accurate administration
Drug disposal advisories recommend utilization of drug take-back programs or safe flushing methods
Patient information leaflets emphasizing safe use, risk of addiction, and overdose prevention
Special formulations tailored for specific patient needs including difficulty swallowing or dose titration
Availability as generic and branded products ensures accessibility and cost-effectiveness
Compliance packaging options such as blister packs to improve adherence in chronic pain patients